Vida Health's 2-Drug Mandate Before $1,000/Month Zepbound Sparks Regulatory Risk

For venture-funded digital health companies targeting the employer obesity-drug market, Vida Health’s recent misstep is a cautionary tale. While its cardiometabolic program promised cost savings and better outcomes, the NPR report reveals a practice that could erode user trust and trigger legal challenges. Investors should watch closely: if regulators crack down on step-therapy gatekeeping, the entire obesity telehealth startup sector—projected to be worth billions—could face a reckoning.

Primary care doctors are increasingly voicing alarm over a new gatekeeping role adopted by telehealth companies in the booming market for obesity drugs. The case of David Davis, a 57-year-old power plant worker from Aptos, California, illustrates the friction. Davis was prescribed Zepbound (tirzepatide) by his primary care physician in December 2025 to treat obstructive sleep apnea—a condition that, alongside obesity, is increasingly managed with GLP-1 therapies. But when Davis tried to fill his prescription, his employer’s health plan required him to first engage with Vida Health, a digital 'cardiometabolic weight loss solution.' What followed was a months-long odyssey of blood tests, questionnaires, and video consults, culminating in a Vida nurse insisting Davis try two generic drugs—naltrexone and bupropion—neither approved for sleep apnea, before the health plan would cover the branded GLP-1. Davis eventually abandoned the process in frustration.

“

As the price of GLP-1 receptor agonists like Zepbound and Wegovy has soared past $1,000 per month per patient, employers—who foot the bill for most insured Americans—have scrambled to contain costs.

His experience is not unique. As the price of GLP-1 receptor agonists like Zepbound and Wegovy has soared past $1,000 per month per patient, employers—who foot the bill for most insured Americans—have scrambled to contain costs. Many have turned to digital health vendors such as Vida Health, Calibrate, and Found, promising lifestyle support and “appropriate” prescribing oversight. But critics say these intermediaries are primarily mechanisms to impose step therapy: forcing patients to try cheaper, often off-label, alternatives before accessing expensive brand-name drugs. The result is a collision between evidence-based medicine and financial stewardship.

For primary care physicians, the intrusion is a direct assault on clinical autonomy. 'These companies are practicing medicine without a license,' one California doctor told NPR, arguing that a telehealth nurse’s mandate to trial unapproved generics for a distinct condition disregards the specialist knowledge of the treating physician. The American Academy of Family Physicians (AAFP) has expressed concern that such practices fragment care and may harm patients—particularly those with comorbidities like sleep apnea, where untreated disease raises cardiovascular risk.

From a market perspective, the trend underscores a broader shift in obesity drug management. The GLP-1 market is projected to exceed $100 billion annually by 2030, driven by expanding indications (sleep apnea, cardiovascular disease, NASH). But employer tolerance for the drug spend is waning. A 2025 Mercer survey found that 40% of large employers now cover GLP-1s for weight loss, but nearly half of those impose prior authorization requirements, and 28% have implemented step therapy. Telehealth companies have capitalized on this demand, pitching cost savings of 15–30% through their programs. However, the Vida Health episode reveals the potential downsides: patient abandonment, eroded trust, and possible legal liability if off-label prescribing leads to adverse events.